Log In
Print
BCIQ
Print
Print this Print this
 

patisiran (ALN-TTR02, GENZ438027, GZ438027)

  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionRNAi therapeutic targeting the transthyretin (TTR) gene using second-generation lipid nanoparticle technology
Molecular Target Transthyretin (TTR)
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA
Latest Stage of DevelopmentPhase III
Standard IndicationAmyloidosis
Indication DetailsTreat familial amyloidotic polyneuropathy (FAP); Treat transthyretin (TTR)-mediated amyloidosis
Regulatory Designation

U.S. - Fast Track (Treat familial amyloidotic polyneuropathy (FAP));
U.S. - Orphan Drug (Treat familial amyloidotic polyneuropathy (FAP))

Partner

Sanofi


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today